PE20141397A1 - Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas de la v1a - Google Patents

Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas de la v1a

Info

Publication number
PE20141397A1
PE20141397A1 PE2014000394A PE2014000394A PE20141397A1 PE 20141397 A1 PE20141397 A1 PE 20141397A1 PE 2014000394 A PE2014000394 A PE 2014000394A PE 2014000394 A PE2014000394 A PE 2014000394A PE 20141397 A1 PE20141397 A1 PE 20141397A1
Authority
PE
Peru
Prior art keywords
triaza
oxa
benzo
blueens
cyclohexil
Prior art date
Application number
PE2014000394A
Other languages
English (en)
Inventor
Cosimo Dolente
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20141397A1 publication Critical patent/PE20141397A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE OXI-CICLOHEXIL-4H,6H-5-OXA-2,3,10b-TRIAZA-BENZO[e]AZULENOS DE FORMULA (I) DONDE R1 ES HALOGENO; R2 ES HETEROARILO, ARILO, CICLOALQUILO(C3-C7), ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON OH, HALOGENO, CN, ALCOXI(C1-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 8-CLORO-1-(4-ISOPROPOXI-CICLOHEXIL)-4H,6H-5-OXA-2,3,10b-TRIAZA-BENZO[e]AZULENO; 1-(4-SEC-BUTOXI-CICLOHEXIL)-8-CLORO-4H,6H-5-OXA-2,3,10b-TRIAZA-BENZO[e]AZULENO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE VASOPRESINA V1a SIENDO UTILES EN EL TRATAMIENTO DE DISMENORREA, HIPERTENSION, SINDROME NEFROTICO
PE2014000394A 2011-09-26 2012-09-24 Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas de la v1a PE20141397A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11182796 2011-09-26

Publications (1)

Publication Number Publication Date
PE20141397A1 true PE20141397A1 (es) 2014-10-13

Family

ID=46881068

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000394A PE20141397A1 (es) 2011-09-26 2012-09-24 Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas de la v1a

Country Status (22)

Country Link
US (1) US8828989B2 (es)
EP (1) EP2760871B1 (es)
JP (1) JP5909554B2 (es)
KR (1) KR101682777B1 (es)
CN (1) CN103827121B (es)
AR (1) AR087999A1 (es)
AU (1) AU2012314593B2 (es)
BR (1) BR112014006945A2 (es)
CA (1) CA2844581A1 (es)
CL (1) CL2014000717A1 (es)
CO (1) CO6870036A2 (es)
CR (1) CR20140092A (es)
EA (1) EA024990B1 (es)
EC (1) ECSP14013271A (es)
IN (1) IN2014CN02169A (es)
MA (1) MA35535B1 (es)
MX (1) MX2014003643A (es)
PE (1) PE20141397A1 (es)
SG (1) SG2014010607A (es)
TW (1) TWI553013B (es)
UA (1) UA111623C2 (es)
WO (1) WO2013045373A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200102069T2 (tr) 1999-01-19 2001-11-21 Ortho-Mcneil Pharmaceutical, Inc. Vasopresin reseptörü antagonistleri olarak trisiklik benzodiazepinler.
US6765004B1 (en) 1999-06-17 2004-07-20 Ortho-Mcneil Pharmaceutical, Inc. Indoloazepines as vasopressin receptor antagonists
GB0303852D0 (en) * 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
US7119088B2 (en) 2003-02-19 2006-10-10 Pfizer Inc. Triazole compounds useful in therapy
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
CA2578370A1 (en) * 2004-08-25 2006-03-02 Pfizer Inc. Triazolobenzodiazepines and their use as vasopressin antagonists
MX2011005119A (es) 2008-11-18 2011-05-30 Hoffmann La Roche Alquilciclohexileteres de dihidrotetraazabenzoazulenos.
BRPI0922303B1 (pt) 2008-11-28 2019-11-12 Hoffmann La Roche arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos, seu processo de preparação, composição farmacêutica que os compreende e uso

Also Published As

Publication number Publication date
EA201490558A1 (ru) 2014-06-30
CA2844581A1 (en) 2013-04-04
AR087999A1 (es) 2014-04-30
BR112014006945A2 (pt) 2017-04-04
KR20140079790A (ko) 2014-06-27
CL2014000717A1 (es) 2014-10-03
JP2014527993A (ja) 2014-10-23
CR20140092A (es) 2014-03-20
EP2760871B1 (en) 2018-07-18
CN103827121B (zh) 2016-08-03
WO2013045373A1 (en) 2013-04-04
IN2014CN02169A (es) 2015-05-29
NZ620653A (en) 2016-03-31
AU2012314593A8 (en) 2014-03-27
MX2014003643A (es) 2014-04-30
SG2014010607A (en) 2014-05-29
CN103827121A (zh) 2014-05-28
US20130079333A1 (en) 2013-03-28
EP2760871A1 (en) 2014-08-06
KR101682777B1 (ko) 2016-12-05
CO6870036A2 (es) 2014-02-20
US8828989B2 (en) 2014-09-09
TW201315737A (zh) 2013-04-16
JP5909554B2 (ja) 2016-04-26
AU2012314593A1 (en) 2014-02-20
TWI553013B (zh) 2016-10-11
UA111623C2 (uk) 2016-05-25
ECSP14013271A (es) 2014-05-31
MA35535B1 (fr) 2014-10-02
AU2012314593B2 (en) 2016-09-29
EA024990B1 (ru) 2016-11-30

Similar Documents

Publication Publication Date Title
NI201300074A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos.
PE20160589A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
ECSP15031579A (es) Lactamas Fusionadas de Arilo y Heteroarilo
MY175272A (en) Novel benzimidazole derivatives as ep4 antagonists
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
CL2013002902A1 (es) Compuestos del acido propanoico derivados dek 3-(acetil-amino-fenil)-fenil; procedimiento de preparacion de los compuestos; composicion farmaceutica; y uso como activadores de la forma libre de hemo de la guanilato ciclasa soluble, en el tratamiento de insuficiencia cardiaca, angina de pecho, hipertension, afecciones tromboembolicas, isquemias, entre otras.
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
CO6771441A2 (es) Compuestos de triazolopiridina como inhibidores de cinasa pim
UY32574A (es) Antagonistas del receptor cxcr3
MX340233B (es) Agonistas de receptores de neurotrofina y sus usos como medicamentos.
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
CL2013002412A1 (es) Compuestos derivados de (piperidin-4-il)-ureas; composicion farmaceutica; y uso como antagonistas del receptor grelina en el tratamiento de la obesidad, trastornos alimenticios, diabetes, caquexia causada por el cancer, insuficiencia cardiaca congestiva, entre otras.
MX352548B (es) Compuestos disustituidos de tetrahidrofuranilo como antagonistas de receptor de bradiquinina b1.
EA201400854A1 (ru) 4-(бензоимидазол-2-ил)тиазольные соединения и родственные аза производные
EA201391056A1 (ru) Гетероарильные соединения в качестве лигандов 5-htрецептора
PE20160842A1 (es) Piperidiniltetrahidroquinolinas sustituidas
EA201290229A1 (ru) Производные спиролактама и их применение
EA201391124A1 (ru) Новые бензодиоксолпиперазиновые соединения
MA32479B1 (fr) Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques
PE20120500A1 (es) Piperidinas sustituidas con heteroilamino y aroilamino como inhibidores de glyt-1
UY32226A (es) Derivados de (dihidro)naftiridinona como antagonistas del receptor de histamina h3
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.

Legal Events

Date Code Title Description
FC Refusal